Study Stopped
Poor accrual and lack of funding
Sponsor study identifier
Secondary identifiers
OTHER · Amsterdam UMC
NIH
interventional
8
1 country
1
Study Start
November 16, 2023
Actual (reported)Primary Completion
June 24, 2026
Actual (reported)Study Completion
June 24, 2026
Actual (reported)The focus of this cross-sectional study is to determine the effects of tissue-specific (adipose tissue or muscle) vs global (combined) insulin resistance (IR) on hepatic triglyceride biosynthesis in humans, and to determine differential effects of an acute exercise intervention on hepatic triglyceride biosynthesis in these groups.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 24, 2026
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 15, 2023
Actual (reported)February 24, 2023
Actual (reported)November 16, 2023
Actual (reported)June 24, 2026
Actual (reported)June 24, 2026
Actual (reported)Effect of tissue-specific insulin resistance on contribution of DNL to plasma triglyceride
The amount of de novo lipogenesis (DNL) in VLDL-triglycerides after a standard meal will be measured in plasma from whole blood. Relationship between DNL and 1) whole body (skeletal muscle) insulin resistance and 2) white adipose tissue insulin resistance will be assessed individually.
Baseline
Change in DNL in VLDL-triglycerides after a standard meal compared to a standard meal with premeal exercise.
The amount of de novo lipogenesis (DNL) in VLDL-triglycerides after a standard meal vs after a standard meal with premeal exercise will be measured in plasma from whole blood.
study visit 1 and study visit 2, up to 8 weeks
Change in plasma triglycerides after a standard meal compared to a standard meal with premeal exercise
study visit 1 and study visit 2, up to 8 weeks
Baseline plasma triglycerides
baseline
Adipose insulin sensitivity
Baseline
Skeletal muscle/whole-body insulin sensitivity assessed by oral glucose tolerance test (OGTT)
Baseline
Participants with global IR and tissue-specific IR. Participants with global IR (in both skeletal muscle and adipose tissue) and tissue-specific IR (in adipose tissue). Glucose tolerance, skeletal muscle/whole-body insulin sensitivity and adipose tissue insulin sensitivity will be evaluated prior to intervention. Contribution of DNL to hepatic VLDL will be measured using a deuterated water drink, to be ingested prior to the standardized dinner. Blood will be drawn the following morning for the measurement of deuterium incorporation into triglycerides. Plasma deuterium will be allowed to wash out over several weeks, and the 2nd deuterated water study will be performed.
Participants with global IR and tissue-specific IR. Participants with global IR (in both skeletal muscle and adipose tissue) and tissue-specific IR (in adipose tissue). Glucose tolerance, skeletal muscle/whole-body insulin sensitivity and adipose tissue insulin sensitivity will be evaluated prior to intervention. DNL will be assessed in all participants after a single day with short bouts of premeal exercise with a standardized dinner. Contribution of DNL to hepatic VLDL will be measured using a deuterated water drink, to be ingested prior to the standardized dinner. Blood will be drawn the following morning for the measurement of deuterium incorporation into triglycerides. Plasma deuterium will be allowed to wash out over several weeks, and the 2nd deuterated water study will be performed.
De novo lipogenesis (DNL) will be assessed in all participants with a standardized dinner
DNL will be assessed in all participants with short bouts of premeal exercise with a standardized dinner
AMC Amsterdam
Amsterdam, Netherlands
Daniel F Vatner, MD, PhD
Yale University
8 participants (actual enrollment reported by the registry).
First Submitted
February 15, 2023
First Posted
February 24, 2023
Study Start
Basic Research Study to Examine the Relation Between Muscle Insulin Resistance and Lipid Production in the Liver.
Contact the study team to confirm eligibility.
November 16, 2023
Actual (reported)Primary Completion
June 24, 2026
Actual (reported)Study Completion
June 24, 2026
Actual (reported)Last Updated
October 27, 2026
Record last verified: 2026-10
By reasonable request, PI can be reached by email, and individual participant data (OGTT results, fasting plasma data, DNL data) will be provided electronically.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: